Clinical trials: Healthy Young Volunteers
Alzheimer's Disease
GSK2647544 RD, DDI in Healthy Young and Elderly Volunteers
GSK2647544 is an orally available, selective inhibitor of Lp PLA2 that is being developed for the treatment of Alzheimer's disease.
- Trial name
- NCT01978327
- Testing
- GSK2647544, drug-drug interaction
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diabetes, Healthy
Comparison of the Effect of Liraglutide in Young Versus Elderly Healthy Volunteers
This trial is conducted in Europe. The aim of this trial is to compare the exposure of liraglutide in young versus elderly healthy subjects.
- Trial name
- NCT01507337
- Testing
- liraglutide
- Where
- Germany
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Alzheimer Disease
Study Evaluating the Safety of Lecozotan SR in Healthy Young and Elderly Subjects
To assess the safety, tolerability and pharmacokinetics of single and multiple ascending oral doses of lecozotan SR in healthy young and elderly subjects.
- Trial name
- NCT00366483
- Testing
- Lecozotan SR
- Where
- France
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Geriatrics, Healthy
Elafibranor Pharmacokinetic Parameters in Elderly Healthy Volunteers
In the elderly, pharmacokinetics is altered. Gastric juice pH is elevated which influences drug solubility and absorption. Drug distribution is decreased in the elderly because of decreased cardiac output, increased peripheral…
- Trial name
- NCT04171752
- Testing
- elafibranor
- Where
- France
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Genfit
Healthy Japanese Young and Elderly Male and Non-fertile Female Volunteers
A Two-part Single and Multiple Dose Study to Assess the Safety , Pharmacokinetics and Effects of AZD3293 in Healthy Japanese Young and Elderly Volunteers
This study consists of two parts, ie, single dose part with young healthy subjects (Part 1) and single and multiple dose part with elderly healthy subjects (Part 2), to assess the safety, tolerability, pharmacokinetics and…
- Trial name
- NCT02005211
- Testing
- AZD3293
- Where
- Japan
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Volunteers
Safety and Tolerability Study of Lu AG06466 in Healthy Young Japanese and Caucasian Participants
The main goal of this study is to evaluate the effect of Lu AG06466 on the body and what the body does to Lu AG06466 after single and multiple doses to healthy Japanese and Caucasian participants.
- Trial name
- NCT05177029
- Testing
- Lu AG06466
- Where
- Japan
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Psoriasis
Study to Assess the Safety and Tolerability of PBF-1650 in Healthy Volunteers.
Single center, randomized, double-blind, placebo-controlled clinical study to assess the safety and tolerability of PBF-1650 in order to obtain the Maximum Tolerated Dose (MTD).
- Trial name
- ADENOIMMUNE (NCT03798236)
- Testing
- PBF-1650 oral capsules
- Where
- Spain
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Palobiofarma SL
Healthy
Single Increasing Doses of BIII 890 CL in Healthy Young Male Volunteers and in Healthy Elderly Male and Female Volunteers
Safety, tolerability and pharmacokinetics of BIII 890
- Trial name
- NCT02269215
- Testing
- BIII 890 CL
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Alzheimer's Disease
A Study to Evaluate the Pharmacokinetics and Safety of BEY2153 in Healthy Participants
This is a first in human Phase 1 study to evaluate the safety, tolerability and pharmacokinetics with healthy young and elderly adult male volunteers after receiving single and multiple ascending dose of BEY2153.
- Trial name
- NCT04476303
- Testing
- BEY2153
- Where
- South Korea
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- BeyondBio Inc.
Deep Vein Thrombosis Leg
A Healthy Volunteer Study to Evaluate for a Single Dose of 4 Different Tablets of DPOC-4088 the Absorption and Elimination From the Body and the Potential Effect on Blood Clotting
This will be a study existing of 4 periods, to evaluate for a single dose of 4 different tablets of DPOC-4088 the absorption and elimination from the body and the potential effect on blood clotting.
- Trial name
- NCT01347203
- Testing
- DPOC-4088
- Where
- Belgium
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Diakron Pharmaceuticals
Healthy
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of BI 1181181 in Healthy Male Volunteers
To assess the reduction of ß-amyloid levels in cerebrospinal fluid and plasma and to evaluate pharmacokinetics, safety and tolerability following single oral doses of BI 1181181.
- Trial name
- NCT02106247
- Testing
- BI 1181181 high dose, BI 1181181 low dose
- Where
- Belgium
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy Volunteers, Pharmacodynamics of Mirabegron
A Study in Healthy Young Men to Look at What Drives the Cardiovascular Effects After Dosing With Mirabegron.
To explore what is driving heart-rate increases after dosing with mirabegron. Subjects will be given a beta-blocker at the same time as mirabegron.
- Trial name
- NCT01284868
- Testing
- mirabegron, Bisoprolol, propranolol
- Where
- France
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
Community-acquired Infection
A Four Part Study to Investigate Relative Bioavailability, Safety and Tolerability of up to 5 Oral Formulation of GSK2251052 in Order to Identify a Formulation for Further Evaluation in a Future Later Phase Study
GSK2251052 is a member of a novel mechanistic and structural class of antibiotics that inhibits the bacterial enzyme leucyl tRNA synthetase (LeuRS) by forming a boron adduct with tRNA and is currently in development for the…
- Trial name
- Relative Bio (NCT01702350)
- Testing
- GSK2251052
- Where
- Australia
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Contraception
A Study to Evaluate Inhibition of Ovulation of Two Oral Estrogen/Progestogen Regimens in Healthy, Young Females Over a Period of 3 Treatment Cycles
Investigation of a new pill containing an estrogen and a progestin in order to monitor the inhibition of the ovulation in young healthy females over 3 treatment cycles
- Trial name
- NCT00631124
- Testing
- BAY86-4891 (Estradiol / Drospirenone)
- Where
- 2 sites in Germany
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Bayer
Healthy Volunteers
A Study of RSV-HMPV Bivalent Vaccine VXB-241 in Older Adults
The main purposes of this study are to assess the safety, reactogenicity and immunogenicity of 4 dose levels of the bivalent combination Respiratory Syncytial Virus (RSV) / human Metapneumovirus (hMPV) vaccine candidate VXB-241…
- Trial name
- NCT06556147
- Testing
- VXB-241 60 mcg (Low Dose), VXB-241 120 mcg (Medium Dose), VXB-241 240 mcg (Medium-high Dose)
- Where
- 4 sites in Australia
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Sanofi
Part A Healthy Young Males and Non-fertile Female Volunteers Aged 20 to 45 Years., Part B Healthy Young Males and Non-fertile Female Volunteers Aged 20 to 45 and Elderly Volunteers Aged 60 to 80
To Investigate the Safety, Tolerability and Pharmacokinetics of AZD2516 After Multiple Dosing in Healthy Volunteers
AZD2516 is being developed for the oral treatment of chronic neuropathic pain. This study is split in to two parts. Part A will measure the effect of food and a new formulation of the drug in the blood and see how well it is…
- Trial name
- NCT01148095
- Testing
- AZD2516
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Volunteers, Pharmacologic Action
A Phase I Study in Healthy Volunteers to Assess the Effect of Cytochrome3A4 (CYP3A4) Inhibitors (Diltiazem and Itraconazole) on the Pharmacokinetics (PK) of AZD3293 and the Effects of AZD3293 on the Pharmacokinetics of Midazolam, a Cytochrome 3A4 and Cytochrome 3A5 (CYP3A4/CYP3A5) Substrate
This study is a single-center, open-label, 3-group, fixed-sequence drug-drug interaction study to assess the effect of coadministration of multiple-dose itraconazole or diltiazem on the single-dose PK of AZD3293 and the effects…
- Trial name
- AZD3293DDI (NCT02010970)
- Testing
- Group 1 AZD3293, Group 2 AZD3293, Group 3 AZD3293
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
Multiple Rising Dose of BI 1181181 Given Orally in Young Healthy Male and Elderly Healthy Male/Female Volunteers
The primary objective of the current study is to investigate the safety and tolerability of BI 1181181 in healthy young male and elderly male and female volunteers following oral administration of repeated rising doses of BI…
- Trial name
- NCT02254161
- Testing
- BI 1181181 healthy elderly, BI 1181181 Healthy young
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of BI 425809 Tablets for 12 Days to Young and Elderly Healthy Male and Female Volunteers and Comparison of Pharmacokinetics of a Single Oral Dose of BI 425809 (Morning Versus Evening)
The aim of the study is to investigate the safety, tolerability, and pharmacokinetics of multiple rising doses of BI 425809 tablets given orally once daily for 12 days to young and elderly healthy male and female volunteers and…
- Trial name
- NCT02337283
- Testing
- BI 425809
- Where
- Germany
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Study To Evaluate The Safety And Tolerability Of Different Doses Of PF-03049423 In Healthy Adult Volunteers And Healthy Older Volunteers
The purpose this study is to evaluate the safety and toleration of PF-03049423 following multiple dose administration as an oral solution to healthy young adult volunteers and healthy elderly volunteers.
- Trial name
- NCT01161069
- Testing
- PF-03049423
- Where
- Belgium
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Pfizer